Spironolactone (Spir) is a selective and competitive antagonist of aldosterone that increases the excretion of water and sodium while decreasing the excretion of potassium (K+ sparing diuretic). The substance was studied to develop qualitative and quantitative methods of analysis and to validate them according to documents regulating the quality of active pharmaceutical ingredients in the development of pharmaceutical forms
Osteoporosis remains a major public health issue, particularly affecting the elderly, and is characterized by decreased bone mass and deterioration of bone structure, increasing the risk of severe fractures. The development of specific and precise tools that allow for the identification and estimation of the influence of modifiable factors on the development of osteoporosis is an important step in early intervention for at-risk individuals